Biodeal Pharmaceuticals Raises Rs 385 Crore from RMB Capitalworks for Expansion and R&D
Biodeal Pharmaceuticals secured Rs 385 crore from RMB Capitalworks, a unit of South African lender FirstRand Bank, marking its first equity raise in two decades. The investment will support the company's expansion into new segments and research and development of new molecules. Biodeal reported Rs 325 crore revenue with a 20% operating margin in FY26 and aims to grow revenue to Rs 500 crore in FY27 and Rs 1,200 crore by FY30 through new launches and expansion enabled by this funding.
First-hand measurement across 2 sources
We measured how 2 outlets covered this story. No outlet gave this story a measurable political slant — there is no left–right reading to report. Overall sentiment is positive (66/100). Lens Score 39/100.
Outlets measured: freepressjournal, news18. See how each one headlined and framed the same story in the source comparison below.
AI Analysis
Sentiment was consistent across outlets (65–68/100), indicating broadly factual reporting rather than editorialising.
Coverage timeline
news18 broke this story on 10 Aug, 11:17 am. Other outlets followed.
- 1